Grufity logoGrufity logo

Exact Sciences Corp Stock Research

EXAS

67.38USD+1.10(+1.66%)Market Closed

Market Summary

USD67.38+1.10
Market Closed
1.66%

EXAS Alerts

EXAS Stock Price

EXAS RSI Chart

EXAS Valuation

Market Cap

11.8B

Price/Earnings (Trailing)

-18.91

Price/Sales (Trailing)

5.66

EV/EBITDA

-22.43

Price/Free Cashflow

-26.92

EXAS Price/Sales (Trailing)

EXAS Profitability

Operating Margin

72.44%

EBT Margin

-30.35%

Return on Equity

-20.49%

Return on Assets

-10.01%

Free Cashflow Yield

-3.71%

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

2.1B

Revenue Y/Y

16.71%

Revenue Q/Q

5.72%

EXAS Earnings

Earnings (TTM)

-623.5M

Earnings Y/Y

42.09%

Earnings Q/Q

14.13%

Price Action

52 Week Range

29.2776.94
(Low)(High)

Last 7 days

0.2%

Last 30 days

2.5%

Last 90 days

31.4%

Trailing 12 Months

-1.2%

EXAS Financial Health

Current Ratio

2.38

EXAS Investor Care

Shares Dilution (1Y)

2.45%

Diluted EPS (TTM)

-3.54

Peers (Alternatives to Exact Sciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
99.8B
27.3B
-4.19% 39.66%
21.72
3.66
-0.09% -26.23%
58.1B
19.3B
-4.61% -16.03%
6.95
3.02
4.29% -31.47%
15.6B
3.4B
-10.55% -10.18%
45.92
4.61
13.67% -64.09%
11.8B
2.1B
2.51% -1.24%
-18.91
5.66
17.95% -4.68%
MID-CAP
6.0B
1.6B
6.39% -14.17%
32.84
3.72
12.27% -21.11%
3.6B
5.4B
-7.30% -56.29%
13.33
0.66
3.46% 13.48%
3.1B
108.5M
-21.66% -32.82%
-9.55
28.71
122.90% -12.19%
2.6B
278.3M
-26.06% -48.44%
-16.69
9.26
92.72% 15.56%
SMALL-CAP
680.4M
-
-13.75% -31.50%
-13.59
291.16
-34.21% -22.31%
519.7M
2.0B
-33.63% -92.58%
-0.79
0.26
72.89% 62.27%
199.8M
80.7M
-24.99% -55.14%
7.06
4.15
13.30% 130.72%
143.9M
60.3M
-71.28% -88.95%
-0.29
2.39
17.51% -38.93%
15.6M
-
-26.15% -25.71%
-0.24
-
- -67.11%
14.4M
-
-6.77% -46.09%
-2.09
-
- 20.96%

Financials for Exact Sciences

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue3.9%2,084,279,0002,005,096,0001,938,402,0001,851,581,0001,767,087,000
Cost Of Revenue5.1%574,394,000546,300,000514,101,000483,469,000458,757,000
  S&GA Expenses-8.1%846,011,000920,104,000929,024,000907,929,000861,889,000
  R&D Expenses1.5%393,400,000387,586,000372,129,000372,281,000385,600,000
EBITDA15.7%-514,945,333-611,176,333-633,140,333-644,919,000-
EBITDA Margin18.9%-0.25-0.30-0.44-0.35-
Earnings Before Taxes13.0%-632,570,000-727,497,000-746,416,000-751,489,000-842,506,000
EBT Margin16.4%-0.30-0.36-0.52-0.41-
Interest Expenses7.1%19,634,00018,330,00018,885,00018,744,00018,606,000
Net Income13.0%-623,506,000-716,372,000-734,549,000-745,398,000-595,625,000
Net Income Margin16.3%-0.30-0.36-0.51-0.40-
Free Cahsflow12.6%-438,021,000-501,146,000-495,227,000-355,232,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-1.3%6,2276,3076,4376,4916,685
  Current Assets-6.3%9821,0491,1021,2151,426
    Cash Equivalents3.1%242235213190315
  Inventory3.1%118115115113105
  Net PPE10.0%685623580--
  Goodwill0.0%2,3462,3452,3462,3352,335
Liabilities-0.4%3,1843,1983,2283,2323,297
  Current Liabilities-2.6%413424443481517
Shareholder's Equity-2.1%3,0433,1093,2093,2583,388
  Retained Earnings-4.1%-3,265-3,137-2,988-2,822-2,641
  Additional Paid-In Capital0.9%6,3126,2556,2056,0866,029
Shares Outstanding0.4%178177177176174
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations25.5%-223-300-300-198-102
  Share Based Compensation-4.6%207217172114253
Cashflow From Investing-64.8%74.0021196.00-719-1,082
Cashflow From Financing41.2%76.0054.0054.004.008.00

Risks for EXAS

What is the probability of a big loss on EXAS?

100%


Probability that Exact Sciences stock will be more than 20% underwater in next one year

78.8%


Probability that Exact Sciences stock will be more than 30% underwater in next one year.

51.9%


Probability that Exact Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EXAS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Exact Sciences was unfortunately bought at previous high price.

Drawdowns

Returns for EXAS

Cumulative Returns on EXAS

20.8%


10-Year Cumulative Returns

40.4%


7-Year Cumulative Returns

8.5%


5-Year Cumulative Returns

6.6%


3-Year Cumulative Returns

What are the long-term rolling returns for EXAS?

FIve years rolling returns for Exact Sciences.

Annualized Returns

Which funds bought or sold EXAS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
added
2.45
87,764,800
244,147,000
0.25%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.05
338,407
984,407
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-28.71
14,000
172,000
-%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
unchanged
-
476
2,476
-%
2023-02-28
Voya Investment Management LLC
reduced
-0.58
532,655
1,565,660
-%
2023-02-27
ST GERMAIN D J CO INC
new
-
16,091
16,091
-%
2023-02-24
NATIXIS
sold off
-100
-10,880,000
-
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
28.11
1,188,000
2,434,000
0.03%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
1,725
10,725
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
1,153
6,153
-%

1–10 of 42

Latest Funds Activity

Are funds buying EXAS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own EXAS
No. of Funds

Exact Sciences News

TheStreet

Cathie Wood's ARKK ETF Pressured a Bit. Has It Bottomed?.

TheStreet,
2 hours ago

InvestorPlace

Schedule 13G FIlings of Exact Sciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
ark investment management llc
9.03%
16,040,490
SC 13G/A
Feb 09, 2023
vanguard group inc
9.71%
17,252,465
SC 13G/A
Feb 07, 2023
blackrock inc.
6.4%
11,354,134
SC 13G/A
Feb 06, 2023
wellington management group llp
5.86%
10,404,476
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
3.7%
6,464,337
SC 13G/A
Mar 10, 2022
price t rowe associates inc /md/
10.7%
18,724,736
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
8.0%
13,788,133
SC 13G/A
Feb 11, 2022
capital world investors
2.7%
4,682,850
SC 13G/A
Feb 09, 2022
ark investment management llc
7.83%
13,496,014
SC 13G
Feb 04, 2022
blackrock inc.
5.5%
9,497,012
SC 13G

EXAS Fair Value

Exact Sciences fair value in different scenarios

The table shows the Fair Value estimates for Exact Sciences for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

5.60

-91.69%

7.74

-88.51%

14.15

-79.00%

26.51

-60.66%

51.53

-23.52%
Current Inflation

5.43

-91.94%

7.34

-89.11%

12.90

-80.85%

23.46

-65.18%

44.74

-33.60%
Very High Inflation

5.23

-92.24%

6.85

-89.83%

11.41

-83.07%

19.92

-70.44%

36.93

-45.19%

Historical Exact Sciences Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Exact Sciences

View All Filings
Date Filed Form Type Document
Mar 17, 2023
424B7
Prospectus Filed
Mar 17, 2023
8-K
Current Report
Mar 07, 2023
4
Insider Trading
Mar 03, 2023
8-K
Current Report
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
8-K
Current Report
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading

Latest Insider Trading transactions for EXAS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-03
ORVILLE JACOB A
sold
-325,000
65.00
-5,000
general manager, screening
2023-03-01
Cunningham Everett
sold
-224,972
62.01
-3,628
chief commercial officer
2023-03-01
Condella Sarah
sold
-62,000
62.00
-1,000
evp, human resources
2023-02-28
Condella Sarah
sold
-178,715
61.12
-2,924
evp, human resources
2023-02-28
Conroy Kevin T
sold
-636,626
61.12
-10,416
president and ceo
2023-02-28
Baranick Brian
sold
-118,084
61.12
-1,932
gen. mgr., precision oncology
2023-02-28
Elliott Jeffrey Thomas
sold
-258,721
61.12
-4,233
chief financial officer
2023-02-28
ORVILLE JACOB A
sold
-411,872
60.2857
-6,832
general manager, screening
2023-02-28
Herriott James
sold
-134,453
60.4283
-2,225
general counsel
2023-02-28
COWARD D SCOTT
sold
-253,831
61.12
-4,153
-

1–10 of 50

Kevin T. Conroy
6500
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenue$ 2,084,279$ 1,767,087$ 1,491,391
Operating expenses:   
Cost of sales (exclusive of amortization of acquired intangible assets)574,394458,757354,324
Research and development393,418385,646554,052
Sales and marketing846,011861,889589,919
General and administrative737,304801,262481,393
Amortization of acquired intangible assets97,45095,00193,398
Impairment of long-lived assets15,96920,210209,666
Total operating expenses2,664,5462,622,7652,282,752
Other operating income (loss)(13,244)023,665
Loss from operations(593,511)(855,678)(767,696)
Other income (expense)   
Investment income (loss), net(19,425)31,7786,574
Interest expense(19,634)(18,606)(67,941)
Total other income (expense)(39,059)13,172(61,367)
Net loss before tax(632,570)(842,506)(829,063)
Income tax benefit9,064246,8815,458
Net loss$ (623,506)$ (595,625)$ (823,605)
Net loss per share - basic (in dollars per share)$ (3.54)$ (3.48)$ (5.45)
Net loss per share - diluted (in dollars per share)$ (3.54)$ (3.48)$ (5.45)
Weighted average common shares outstanding - basic (in shares)176,351171,348151,137
Weighted average common shares outstanding - diluted (in shares)176,351171,348151,137

EXAS Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 242,493$ 315,471
Marketable securities389,564715,005
Accounts receivable, net158,043216,645
Inventory118,259104,994
Prepaid expenses and other current assets73,89874,122
Total current assets982,2571,426,237
Long-term assets:  
Property, plant and equipment, net684,756580,248
Operating lease right-of-use assets167,003174,225
Goodwill2,346,0402,335,172
Intangible assets, net1,956,2402,094,411
Other long-term assets, net90,57774,591
Total assets6,226,8736,684,884
Current liabilities:  
Accounts payable74,91667,829
Accrued liabilities299,216398,556
Operating lease liabilities, current portion28,36619,710
Other current liabilities10,24930,973
Total current liabilities412,747517,068
Convertible notes, net2,186,1062,180,232
Long-term debt50,0000
Other long-term liabilities352,459417,782
Operating lease liabilities, less current portion182,399182,166
Total liabilities3,183,7113,297,248
3183711000
Stockholders’ equity:  
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2022 and December 31, 202100
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—177,925,631 and 173,674,067 shares at December 31, 2022 and December 31, 20211,7801,738
Additional paid-in capital6,311,6446,028,861
Accumulated other comprehensive loss(5,236)(1,443)
Accumulated deficit(3,265,026)(2,641,520)
Total stockholders’ equity3,043,1623,387,636
Total liabilities and stockholders’ equity$ 6,226,873$ 6,684,884